Trial Profile
An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B) -inflamed and normal skin.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2012
Price :
$35
*
At a glance
- Drugs ABT 102 (Primary) ; Etoricoxib; Tramadol
- Indications Pain
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.
- 13 Sep 2010 Primary endpoint 'Pain-measures' has been met.